Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (DE:RPD)
FRANKFURT:RPD
RPD Stock Chart & Stats
Day’s Range― - ―
52-Week Range€23.12 - €33.05
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
$17.05B
Enterprise Value€22.71B
Total Cash (Recent Filing)$1.82B
Total Debt (Recent Filing)$7.62B
Price to Earnings (P/E)13.0
Beta0.42
Next Earnings
Aug 06, 2025EPS Estimate
0.94Last Dividend Ex-Date
May 16, 2025Dividend Yield2.52%
Share Statistics
EPS (TTM)0.37
Shares Outstanding421,370,670
10 Day Avg. Volume15
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio-4.42
Price to Book (P/B)3.08
Price to Sales (P/S)0.00
P/FCF Ratio4.14
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit10.07
Enterprise Value/Ebitda2.93
Forecast
1Y Price Target
$35.88Price Target Upside19.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Royalty Pharma News
Bulls Say, Bears Say
Bulls Say
Growth PotentialThe growth profile is above the peer average.
Portfolio DiversificationThe company's diversified portfolio and insulation from potential tariffs are seen as positives.
Shareholder ConfidenceA $3B share buyback program boosts EPS and exemplifies management confidence.
Bears Say
Cost StructureThe acquisition is expected to reduce costs and enhance economic returns on investments.
Management StructureRPRX is acquiring its external manager in a near-term cash accretive deal, reforming a legacy structure that was a concern to some investors.
Regulatory EnvironmentThe company can adapt to any potential changes in the regulatory environment due to not having an internal 'pipeline'.
Options Prices
Currently, No data available
---
Ownership Overview
1.86% Insiders
19.91%
Mutual Funds
18.11% Other Institutional Investors
44.10% Public Companies and Individual Investors
RPD FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was €23.12 and its highest was €33.05 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $17.05B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Aug 06, 2025 which is in 42 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on May 08, 2025. The company reported €0.368 earnings per share for the quarter, missing the consensus estimate of €0.852 by -€0.484.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of €0.738 which represents an annual dividend yield of 2.52%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 0.94.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 421,370,670 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of €0.368 in its last earnings report, missing expectations of €0.852. Following the earnings report the stock price went up 1.57%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in DE:RPD
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.88 (19.10% Upside)
$35.88 (19.10% Upside)
Blogger Sentiment
Bullish
DE:RPD Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.78%
12-Months-Change
Fundamentals
Return on Equity
16.57%
Trailing 12-Months
Asset Growth
9.16%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPD Company Deck
RPD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Royalty Pharma's strong financial performance, dynamic capital allocation strategy, and significant portfolio expansions, alongside some concerns about policy uncertainties and ongoing disputes. The company remains optimistic about its future growth and market opportunities.Read More>RPD Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPD Stock 12 Month Forecast
Average Price Target
€35.88
▲(19.10%Upside)